- Skip Navigation
- Experience RGW
- Patient Education
- Referring Doctors
- Patient Portal
Completed Study | Duration: 90 days
ALLEGRO PVD is a multi center, prospective, randomized, and placebo-controlled Phase II clinical trial for the induction of Posterior Vitreous Detachment (PVD). There are currently no drugs on the market for this purpose. The new drug, Luminate, is an anti-integrin with the potential to separate the vitreous and retinal layers in the eye by disrupting cellular adhesion. This study is for patients diagnosed with Non-Proliferative Diabetic Retinopathy (NPDR). Participants will be treated and followed for 90 days.
This study is being conducted at our Fairfax office.